Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesVlado Perkovic, Richard Pratley, Katherine R. Tuttle et al.|New England Journal of Medicine|2024Cited by 1.5k
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsSunil V. Badve, Vlado Perkovic|The Lancet Diabetes & Endocrinology|2024Cited by 247
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trialsEllen M. Apperloo, Hiddo J.L. Heerspink, Brendon L. Neuen et al.|The Lancet Diabetes & Endocrinology|2024Cited by 135
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW TrialRichard E. Pratley, Kenneth W. Mahaffey, Katherine R. Tuttle et al.|Journal of the American College of Cardiology|2024Cited by 107
Renoprotection with Semaglutide and Liraglutide:Direct or Indirect Effects?Johannes F.E. Mann, Vlado Perkovic, John B. Buse et al.|Research at the University of Copenhagen (University of Copenhagen)|2019Cited by 0